The European Union's drug regulator said it would assess two new Danish studies that link Novo Nordisk's popular diabetes ...

A vision-threatening eye condition may be linked to Ozempic. Meanwhile, Nearly 80% of doctors are using telemedicine weekly, ...

The maker of weight-loss and diabetes drugs has supercharged the Danish economy — but other businesses complain that’s left ...

Danish pharmaceutical firm Novo Nordisk A/S (NYSE:NVO) announced plans to invest approximately $1.20 billion (8.5 billion ...

Danish health authorities said on Monday they would ask the European Union's drug regulator to review the findings of two ...

Recently published studies assert that Ozempic significantly increases the risk of developing a rare eye condition called non ...

Ozempic maker Novo Nordisk A/S is investing 8.5 billion kroner ($1.2 billion) to build a new major factory in Denmark to help ...

Novo Nordisk's Ozempic will become the first and only GLP-1 drug to be shown to reduce progression of kidney disease in ...

NVO's CagriSema target of up to 25% in long-term weight loss is highly promising vs. 15% through Wegovy and 20% through ...

When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion in sales in 2023, it shows no ...

New studies link diabetes drug Ozempic to increased risk of NAION, a rare eye condition causing vision loss. Danish Medicines ...

Danish pharma company Novo Nordisk, makers of weight-loss drugs Ozempic and Wegovy, plans to expand production based on a ...